Previous Article | Next Article ![]()
Journal of Virology, May 2002, p. 4357-4363, Vol. 76, No. 9
0022-538X/02/$04.00+0 DOI: 10.1128/JVI.76.9.4357-4363.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.
- and Lymphotoxin-ß-Deficient Mice Differ in Susceptibility to Scrapie: Evidence against Dendritic Cell Involvement in Neuroinvasion
Division of Virology, Department of Neuropharmacology, The Scripps Research Institute, La Jolla, California 92037,1 Laboratory of Persistent Viral Diseases, Rocky Mountain Laboratories, Hamilton, Montana 59840,2 Howard Hughes Medical Institute, Section of Immunobiology, Yale University School of Medicine, New Haven, Connecticut 06520,3 Digital Gene Technologies, Inc., La Jolla, California 920374
Received 6 November 2001/ Accepted 28 January 2002
|
|
|---|
) and LT-ß signaling components. We report here that by the oral route, LT-
-/- mice developed scrapie while LT-ß -/- mice did not. Furthermore, LT-
-/- mice had a higher incidence and shorter incubation period for developing disease following inoculation than did LT-ß -/- mice. Transplantation of lymphoid tissues from LT-ß -/- mice, which have cervical and mesenteric lymph nodes, into LT-
-/- mice, which do not, did not alter the incidence of CNS scrapie. In other studies, a virus that is tropic for and alters functions of CD11c+ cells did not alter the kinetics of neuroinvasion of scrapie. Our results suggest that neither FDC nor CD11c+ cells are essential for neuroinvasion after high doses of RML scrapie. Further, it is possible that an as yet unidentified cell found more abundantly in LT-
-/- than in LT-ß -/- mice may assist in the amplification of scrapie infection in the periphery and favor susceptibility to CNS disease following peripheral routes of infection. |
|
|---|
FDCs (8, 9, 17, 23, 25-27) and in recent reports CD11c+ dendritic cells (3) appear to play an important role in the peripheral amplification of infectivity prior to neuroinvasion. In the present study we evaluated the role of FDCs in oral and i.p. infection of mice by scrapie agent. Since FDC generation and maintenance in germinal centers is dependent on lymphotoxin alpha (LT-
) and LT-ß signaling components (2, 4, 13, 15, 20, 39), we infected LT-
and LT-ß knockout mice with scrapie and studied the accumulation of PrPsc in their spleens and brains, the presence of infectious scrapie in their CNS, and the development of progressive neurodegenerative disease. We also investigated whether CD11c+ dendritic cells played an essential role in neuroinvasion of scrapie by using lymphocytic choriomeningitis virus (LCMV) Clone 13, which specifically infects and aborts the function of such CD11c+ cells (21, 35). Interestingly, LT-
-/- mice were found to have a higher disease incidence and shorter incubation period than LT-ß-/- mice despite similar depletion of FDCs. Our results supported the conclusion that neither FDCs nor CD11c+ cells are absolutely required for neuroinvasion in TSE disease caused by the RML strain of mouse scrapie. Further, our findings indicate that in addition to FDCs and CD11c+ cells, a unique cell(s) found more abundantly in LT-
-/- than in LT-ß-/- mice likely assists in the amplification of scrapie infection in the periphery and favors susceptibility for CNS disease following peripheral routes of infection.
|
|
|---|
-/- mice were derived originally by David Chaplin (Washington University, St. Louis, Mo.) (14). RelB-/- mice were made as described previously (10). Genotyping confirmed their LT-
and LT-ß status (10, 14, 20). All mice were on a mixed background of C57Bl/6 and 129/Sv (B6 x 129). CD4, CD8, ß2-microglobulin, and major histocompatibility complex (MHC) class II gene-disrupted mice on B6 background were derived and characterized as reported. Breeding and maintenance of these mice and of C57Bl/6 and BALB/cjd mice were performed under specific-pathogen-free conditions at the Rodent Breeding Colony, The Scripps Research Institute (La Jolla, Calif.).
Infectious agents and infection of mice.
Mice were inoculated by oral, i.p., or intracerebral (i.c.) routes with various doses of the RML strain of mouse scrapie (31). i.p. inoculation volume was 100
, and i.c. inoculation volume was 30
. Oral infection was in a volume of 200
administered via a small-diameter flexible polypropylene catheter inserted over the base of the tongue about 1 to 2 cm into the esophagus (31). Quantitation of infectious scrapie in brains was accomplished by i.c. injection of serial 10-fold dilutions of a 10% brain homogenate into B6 mice (four mice/dilution). The LCMV ARM 53b strain is a triple plaque-purified isolate of ARM CA 1371 and was passaged in baby hamster kidney (BHK) cells (35). Cl 13 is a triple plaque-purified variant of ARM 53b derived from spleen cells of an adult BALB/WEHI mouse persistently infected since birth with ARM 53b (1, 33). Either virus (2 x 106 PFU) was inoculated intravenously (i.v.) into B6 x 129, B6, or BALB/cdj mice (35). Inoculated mice were sacrificed when moribund, or when healthy at 11 to 12 months postadministration of mouse scrapie.
RNase protection assay.
The RNase protection assay was performed using probe sets from Pharmingen (La Jolla, Calif.) where 20 µg of total RNA obtained from brains of control, LT-
-/-, LT-ß-/-, or RelB-/- mice were hybridized to 32P-labeled riboprobes from various sets (16). After digestion with RNase, the material was separated on a sequencing gel, and the intensity of the protected RNA fragments was quantified using an ImageQuant system with appropriate software (Molecular Dynamics). Each transcript level was normalized to the ubiquitous housekeeping L32 RNA.
PrPsc purification. Twenty-percent tissue homogenates were made in a solution containing 0.01 M Tris-HCl (pH 7.4) and 0.005 M MgCl using disposable Konex microcentrifuge tubes and matched pestles. Homogenates were sonicated for 2 min, and then DNase was added (1.0 mg/g of starting tissue) and the suspension incubated for 1 h at 37°C in a swirling water bath. An equal volume of 20% sarcosyl in 0.01 M Tris-HCl (pH 7.4) was added, and the suspension was vortexed and then incubated at room temperature for 1 h. Suspensions were centrifuged at 10,000 x g, 30 min, 10°C, and the resulting supernatant was centrifuged at 215,000 x g for 2 h at 10°C. The resulting pellet was resuspended by sonication in sterile water (1.0 ml/200 mg of starting tissue). Twenty-five micrograms of proteinase K/200 mg of starting tissue was added, and the suspension was incubated at 37°C in a swirling water bath for 30 min. Proteinase K activity was terminated by the addition of 25 µl of 0.1 M phenylmethylsulfonyl fluoride/ml of suspension followed by cooling on ice for 15 min. Suspensions were then centrifuged at 215,000 x g for 1 h at 10°C. Pellets were resuspended in sample buffer by sonication, boiled 5 min, and then frozen until needed. Immunoblotting as described previously (31) was used to detect PrPsc.
|
|
|---|
and LT-ß gene knockout mice.
Injection of 107 50% lethal doses (LD50) of the RML strain of murine scrapie directly into the brains of control (LT-
+/+ and LT-ß+/+), LT-
-/-, or LT-ß-/- mice led to 100% mortality in all groups studied (four to six mice/group) with either death or severe morbidity requiring sacrifice at nearly equivalent times postinoculation (Fig. 1; Table 1). As expected, brains harvested from representative mice of each group expressed PrPsc (Table 1; Fig. 2) and the classic histologic picture of neuronal degeneration, spongiosis, and astrocytosis. In preliminary studies normal control mice receiving 105.5 LD50 orally did not develop TSE by 380 days, whereas all given 107 LD50 orally died before 290 days (five mice/group). Therefore, for all subsequent experiments 107 LD50 of mouse scrapie was administered orally or i.p. When control mice (10 per group) received murine scrapie orally or by the i.p. route with 107 LD50 of RML scrapie, all died by day 288 ± 8 (mean ± 1 standard deviation: oral route) or day 189 ± 5 (i.p. route), expressed PrPsc, and manifested abnormal histopathology in their brains (Table 1). To the contrary and as anticipated, none of the PrP-/- mice inoculated i.c. became clinically ill over a 375-day observation period; these mice did not express PrPsc, nor were histopathologic abnormalities evident in brain tissue.
![]() View larger version (19K): [in a new window] |
FIG. 1. LT- -/- mice and LT-ß-/- mice differ in susceptibility to RML mouse scrapie administered orally or i.p. Control LT- -/- mice and LT-ß-/- mice were 8 weeks old when inoculated. For i.c. inoculation, four control mice, six LT- -/- mice, and six LT-ß-/- mice were used. For oral inoculation, 10 control mice, 10 LT- -/- mice, and 10 LT-ß-/- mice were injected. Similar results occurred after a repeat experiment with six LT- -/- mice and six LT-ß-/- mice. For i.p. inoculation, 10 control mice, 10 LT- -/- mice, and 16 LT-ß-/- mice were employed.
|
|
View this table: [in a new window] |
TABLE 1. Scrapie disease in LT- -/-, LT-ß-/-, RelB-/-, and control micea
|
![]() View larger version (37K): [in a new window] |
FIG. 2. Lack of PrPsc expression in brains of LT-ß-/- mice inoculated orally or i.p. with 107 LD50 of RML mouse scrapie (see Table 1). Lanes 2 and 3 represent two LT- -/- mice inoculated orally, and lanes 7 and 8 show results for two other LT- -/- mice inoculated i.p. All illustrate the expression of PrPsc. As displayed in lanes 4 and 5, no expression of PrPsc was evident in brains of LT-ß-/- mice after oral inoculation or after i.p. inoculation, as in lanes 9 and 10. Similar results were found with additional samples from LT- -/- and LT-ß-/- mice as recorded in Table 1.
|
) or TNF-ß mRNA (Fig. 3).
![]() View larger version (62K): [in a new window] |
FIG. 3. Transcripts of TNF- or -ß mRNA appear in brains of LT- -/- mice receiving 107 LD50 of RML scrapie orally or i.p. These mice develop clinical disease, display histopathologic lesions, and express PrPsc associated with scrapie disease. In contrast, LT-ß-/- mice after oral or i.p. inoculation, or RelB-/- mice after oral administration of scrapie, fail to develop scrapie disease or show transcripts of TNF- or -ß mRNA in their brains. Results were similar for three additional LT-ß-/- mice and one RelB-/- mouse studied (data not shown). Each transcript level was normalized to the ubiquitous housekeeping L32 RNA.
|
-/- mice inoculated orally segregated into two groups. Fifty percent developed clinical scrapie and were sacrificed by day 285 ± 4, whereas the other 50% failed to show clinical disease by day 345 to 360 (Fig. 1; Table 1). As anticipated, those LT-
-/- mice developing clinical scrapie expressed both PrPsc (Fig. 2) and TNF mRNA (Fig. 3) in their brains. Furthermore, infectivity was found in the brains of these mice as detected by inoculation into normal recipients.
The differences between LT-ß-/- and LT-
-/- mice as regards susceptibility to scrapie infection were further confirmed when these mice were given scrapie by the i.p. route. In this instance, 9 of 10 inoculated LT-
-/- mice developed clinical scrapie and had PrPsc in their brains. The onset of disease was significantly (P < 0.01) slower (230 ± 5 days) in these LT-
-/- mice than in age- and sex-matched LT-
+/+ mice (day 189 ± 5) given the same dose of scrapie. The lone clinically healthy LT-
-/- mouse was sacrificed at 348 days after scrapie inoculation, and its brain contained PrPsc and infectious scrapie. In contrast to LT-
-/- mice, only 5 of 16 (31%) LT-ß-/- mice developed TSE disease after i.p. inoculation of scrapie and had PrPsc in their brains, whereas the remaining 11 of 16 (69%) mice did not (Fig. 1 and 2; Table 1). Brains from the latter group also failed to express TNF mRNA (Fig. 3). The mean time interval required for disease to develop was shorter in LT-
-/- mice (day 230 ± 5) than in the LT-ß-/- group (day 295 ± 2) (P < 0.001). Intracerebral inoculation of 10% brain homogenates from five of the i.p.-inoculated clinically healthy, PrPsc nil LT-ß-/- mice into control mice has not led to scrapie over a 345-day observation period.
Enhanced susceptibility of LT-
-/- mice over LT-ß-/- mice is not due to differences in FDC populations of LT-
-/- or LT-ß-/- mice or the presence of cervical and mesenteric lymph nodes or thymic tissues in LT-ß-/- mice.
The enhanced susceptibility of LT-
-/- mice over that of LT-ß-/- mice to both oral and i.p. administration of scrapie, coupled with the longer interval between infection and clinical disease in LT-ß-/- mice (day 295 ± 2) compared to LT-
-/- mice (day 230 ± 5), led us to evaluate both the numbers of FDCs in LT-ß-/- mice versus LT-
-/- mice and possible immunologic protection by cervical and mesenteric lymph nodes or thymic tissues in LT-ß-/- mice. FDCs are known cells in lymphoid organs implicated in the replication of scrapie infectivity (8, 9, 17, 23, 25-27). Examination of three spleens randomly chosen from both LT-
-/- and LT-ß-/- mice, as expected from observations of others (2, 10, 13, 14, 20), showed the absence of FDCs as determined by the use of FDC-M2 antibodies on cryomicrotome sections. Hence, by the assays used, the susceptibility of LT-
-/- mice to peripheral routes of scrapie infection was not attributable to residual or extra FDCs.
LT-ß-/- mice are reported to have cervical and mesenteric lymph nodes, whereas LT-
-/- mice do not (2, 14, 20, 22). However, one report (4) concluded that a subset of LT-
-/- mice have abnormal lymphoid-like structures in their mesenteric fat, perhaps accounting for the biphasic response we noted (Fig. 1). To ascertain whether lymphoid cells might provide resistance against peripheral TSE infection for LT-ß-/- mice, we removed their cervical and mesenteric lymph nodes and initially examined such tissues for FDCs using FDC-M2 antibodies. As anticipated, no FDCs were observed. In a separate series of studies we adoptively transferred cervical and mesenteric lymph node cells i.p. or implanted the tissue with and without thymic tissue from LT-ß-/- mice (four mice/group) under the renal capsule (38) of LT-
-/- mice. One week after transplantation, LT-
-/- mice reconstituted with LT-ß lymphoid cells were challenged with 107 LD50 of RML scrapie i.p. No difference was seen in the time required for developing scrapie in LT-
-/- mice reconstituted with LT-ß lymphoid cells (days 230 to 250) compared to regular LT-
-/- mice. These results indicated it is likely that the cervical and mesenteric lymph nodes and thymic tissue from LT-ß-/- mice had no protective effect against TSE disease.
RelB-/- mice fail to develop TSE after oral administration of mouse scrapie.
RelB-/- mice, like LT-
-/- and LT-ß-/- mice, lack FDCs and exhibit disordered splenic architecture (10). However, unlike LT-
-/- or LT-ß-/- mice, RelB-/- mice also have abnormal thymic medullary cells. RelB-/- mice given scrapie orally failed to develop disease and did not express PrPsc (Table 1) or TNF mRNA in their brains (Fig. 3) over a 1-year observation time (three of three mice). In contrast, i.c. inoculation of scrapie into RelB-/- mice resulted in both a clinical and a histopathologic picture of scrapie disease as well as expression of PrPsc in brain tissues. Therefore, RelB-/- mice, like LT-ß-/- mice, are resistant to orally administered RML scrapie. By contrast, 200 days after oral inoculation of scrapie into RelB+/- or RelB+/+ mice (two to three mice per group), clinical and histopathologic evidence of scrapie as well as expression of PrPsc in the CNS were clear.
Dysfunction of splenic DEC205+ and CD11c+ lymphoid dendritic cells does not alter the kinetics for development of TSE after peripheral administration of mouse scrapie. After i.v. administration of 2 x 106 PFU of LCMV Cl 13, >80% of DEC205+ and CD11c+ dendritic cells are infected (35), splenic architecture is disrupted (7, 21, 28, 35-37), replication occurs primarily in the splenic white pulp (7, 21, 35, 37), and a generalized immunosuppression lasting more than 6 months ensues (7, 35, 37) (unpublished data). By contrast, i.v. inoculation of 2 x 106 PFU of the parental LCMV strain Armstrong (ARM) (which differs by two amino acids from the LCMV Cl 13 variant) (33), yields only minimal infection of DEC205+ and CD11c+ (<10%) cells (35), replicates preferentially in the red pulp of the spleen (21, 35, 36), causes only minimal disorganization of the splenic architecture early in infection, and does not cause immunosuppression (7, 35, 37).
At 12 days after LCMV Cl 13 inoculation, when more than 80% of DEC205+ and CD11c+ cells are infected, immunosuppression is extensive and these dendritic cells cannot act as antigen-presenting cells (7, 35), LCMV-infected mice were given 107 LD50 of RML scrapie orally or i.p. As shown in Table 2 for both oral and i.p. administration of scrapie, mice with and without impairment of their DEC205+ or CD11c+ cells developed TSE disease at equivalent times and had PrPsc and infectious scrapie in their brains. Because the spleen is known to be an important site of amplification and accumulation of scrapie infectivity in mice, we tested spleens of LT-
-/- or LT-ß-/- mice by Western blot analysis for PrPsc and found all to be negative (three of three mice tested per group at 60 and 200 days after scrapie inoculation) in contrast to wild-type control mice and mice coinfected with LCMV and scrapie (data not shown). Overall, these studies suggest that a peripheral cell other than FDCs and interdigitating dendritic cells (DEC205+, CD11c+), and presumably not located in the spleen, might be involved in the amplification of PrPsc.
|
View this table: [in a new window] |
TABLE 2. Study of peripheral scrapie infection in mice with dysfunction of splenic DEC205+ and CD11c+ lymphoid dendritic cellsa
|
|
|
|---|
-/- mice devoid of FDCs undergo neuroinvasion and replication of infectious scrapie after oral inoculation. This neuroinvasion in LT-
-/- mice also occurs after i.p. inoculation. A profound difference in susceptibility to the development of TSE disease occurs in LT-
-/- compared to LT-ß-/- mice. The differences in kinetics and susceptibility of TSE disease between LT-
-/- and LT-ß-/- mice, for both of which groups FDCs are deleted as observed by several investigators (2, 13, 14, 20) and reconfirmed here, suggest the likelihood that an additional, previously unidentified cell type may be important for replication of TSE infectivity. Last, neuroinvasion of scrapie occurred in mice in which the function of CD11c+ cells was compromised. Our results with LT-ß-/- mice inoculated with scrapie i.p. differ slightly from those of Manuelidis et al. (24), who studied i.p. inoculation of LT-ß-/- and LT-ß+/+ mice. These investigators utilized a different source of infectious TSE material, mouse-adapted human Creutzfeldt-Jakob disease, strain Fukuoka-2. After inoculation of 2,000 infectious units, the disease incidence was 100% but a significant increase in the incubation period in LT-ß-/- mice was observed, whereas after 20 infectious units the incidence of disease was lower in LT-ß-/- mice. In contrast, we used a very high dose of the RML strain of mouse scrapie and found a disease incidence of only 5 out of 16 after i.p. infection of LT-ß-/- mice. The differences in incidence of disease observed with LT-ß-/- mice in these experiments may be related to the TSE strains used. For example, the Fukuoka-2 strain may be less dependent on replication in FDCs prior to neuroinvasion than is the RML strain.
Earlier studies detected PrPsc in FDCs from spleens (8, 9, 17, 23, 25-27). However, in our experiments the differences between LT-
-/- and LT-ß-/- mice, for both of which FDCs are deleted, suggest that an additional, previously unidentified cell type is also likely important for replication of TSE infectivity. However, we cannot exclude, although unlikely, the possibility of a small subset of FDCs in LT-
-/- mice that is not recognized by FDC-M2 antibodies and the possibility that this subset of FDCs is missing in LT-ß-/- mice. Recently, Aucouturier et al. (3), using adoptive transfers, reported that CD11c+ splenic dendritic cells from scrapie-infected mice were able to transmit TSE. Our experiments with LCMV Cl 13 and our inability to find PrPsc in spleens of LT-
-/- or LT-ß-/- mice indicate that a cell in addition to DEC205+ or CD11c+ dendritic cells is likely involved. Further, comparing a panel of gene knockout mice suggests that CD4 or CD8 T cells or cells bearing MHC class II molecules are not likely the source of PrPsc amplification. These results are further supported by our lymphoid cell transfer from LT-ß-/- mice into LT-
-/- mice, which failed to alter the kinetics of TSE infection of LT-
-/- mice. Use of high doses of hamster scrapie administered orally or i.p. into mice in which hamster PrP expression was restricted to neurons using the neuron-specific enolase promoter (31, 32) showed that neuroinvasion can occur in the absence of PrP expression in FDCs or CD11c+ cells. While passage of scrapie infection from the peripheral site to the CNS occurs via neuronal transport, FDCs (see review (40) and perhaps CD11c+ dendritic cells play an important role in the amplification of infectivity prior to neuroinvasion, our data here coupled with an earlier report by Klein et al. (19) using TNF receptor 1-/- mice devoid of FDCs suggest that an additional, yet-to-be-defined cell in the periphery can also replicate and amplify scrapie infectivity. Further, LT-
-/- and LT-ß-/- mice handle the RML scrapie agent in distinctive ways, suggesting that these models may be informative for the search of the unknown cell(s). Interestingly and in contrast to these studies with scrapie, LT-
-/- mice and LT-ß-/- mice have been reported to handle another infectious agent equivalently (6).
|
|
|---|
We thank Antoinette Tishon, Chao P. Teng, and Noemi Sevilla for technical assistance; Matthias von Herrath for assistance with the transplantation surgery; Y.-X. Fu for helpful discussions; M. Kosco-Vilbois for the FDC-M2 antibody; and Michael Grusby for the MHC class II-/- mice.
Publication no. 13841-NP from the Department of Neuropharmacology, The Scripps Research Institute, La Jolla, CA 92037. ![]()
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»